Abstract Low-dose antihypertensive drugs in combination are prescribed frequently in clinical practice. Combination treatment is superior to monotherapy with higher doses of each drug in terms of blood pressure reduction and side effects. However, it is unclear whether combination treatment provides additional prognostic benefit beyond the blood pressure lowering effects. We assessed the usefulness of the combined treatment of a renin-angiotensin system inhibitor (RASI) and a calcium channel blocker (CCB) for all cardiovascular events in the Japanese Coronary Artery Disease (JCAD) Study population. In the JCAD Study, which is an observational and non-randomized trial, 13,812 patients with angiographically shown narrowing [50% in C1 of 3 major coronary arteries were followed up for a mean of 2.7 years. The primary endpoint of the study was all cardiovascular events. In the present study, baseline covariates possibly influencing the event rate were adjusted between the different treatment groups. There was no statistically significant difference in the event rate between the RASI monotherapy and combined treatment groups, although Kaplan-Meier analysis showed a 23% (p = 0.0003) relative risk reduction with an RASI monotherapy compared with the control group. In conclusion, there may be no additional benefit beyond blood pressure lowering effects in the combination of an RASI and a CCB in patients with angiographically documented CAD.
Introduction
It is well known that the use of antihypertensive agents in combination provides a synergistic or at least an additive blood pressure reduction, which is greater than higher doses of either drug used as monotherapy [1] [2] [3] [4] . Combination lowdose drug treatment also reduces side effects [1, 2] . The combination of a renin-angiotensin system inhibitor (RASI) and a calcium channel blocker (CCB) is frequently used in clinical practice [5] . Since both an RASI and a CCB possibly provide cardiovascular protection by improving vascular function [6] [7] [8] , it is postulated that combination therapy might provide prognostic benefit beyond the blood pressure lowering effects. Thus, we compared the prognostic effects of an RASI and a CCB alone or in combination beyond the blood pressure lowering effects after adjustment for baseline covariates, including t blood pressure, in the Japanese Coronary Artery Disease (JCAD) Study population [9] .
Materials and methods
The protocol and major outcomes of the JCAD study were previously published [9] . Briefly, we consecutively enrolled patients with angiographically demonstrable narrowing [50% in C1 of 3 major coronary arteries. Initially, 15,628 patients were registered, and 13,812 patients were followed up for a mean of 2.7 years (follow-up rate 88.4%). Clinical events to be registered in the database were defined as allcause deaths, including cardiac, cerebral, vascular and other deaths, and cerebral, cardiac and vascular events. Cerebral events included cerebral hemorrhage, cerebral infarction and transient ischemic attack. Cardiac events consisted of fatal and nonfatal myocardial infarction, unstable angina, congestive heart failure, coronary bypass graft surgery, resuscitated cardiac arrest and cardiopulmonary arrest on arrival. Angiographic restenosis incidentally found during routine follow-up coronary angiography without clinical symptoms was excluded from event registration. Aortic dissection and rupture of an aortic aneurysm were classified as vascular events. The primary endpoint of this present study was all cardiovascular events. The study data were derived from a post-hoc analysis of an observational, non-randomized trial.
Informed consent was obtained from each patient, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.
Statistical analysis
Numerical data are presented as the mean value ± SD. An unpaired Student's t test was applied for the comparison of parametric values, whereas comparisons of variables between the two groups were made by the Wilcoxon test for non-parametric unpaired values. Proportional data were analyzed by the chi-square test. Propensity score matching analysis was used to match baseline characteristics between the two groups [10] . Kaplan-Meier hazard ratios were used to examine the incidence over time, and the logrank test was used to assess group differences. Two-sided p \ 0.05 was regarded as statistically significant.
Results
As shown in Table 1 , baseline covariates potentially influencing the cardiovascular event were adjusted between the two groups by the propensity score matching method. However, systolic blood pressure was slightly but significantly higher (1.3 mmHg in mean) in the control group than in the RASI monotherapy group (Table 1a) , and was slightly but significantly lower (1.9 mmHg in mean) in the control group than in the combination treatment group (Table 1c) . It was also significantly lower (3.1 mmHg in mean) in the RASI monotherapy group than in the combination treatment group (Table 1d) . Kaplan-Meier analysis showed a 23% relative risk reduction of all cardiovascular events with RASI monotherapy compared with the control group. Log-rank test showed a statistically significant difference (p = 0.0003) in the event rate between the two groups (Fig. 1a) . Meanwhile, there was no statistically significant difference in the incidence of all cardiovascular events between the control and the CCB monotherapy groups (Fig. 1b) . Furthermore, no statistically significant difference in the incidence of all cardiovascular events was observed between the control and combination treatment groups (Fig. 1c) . There was also no statistically significant difference in the incidence of all cardiovascular events between the RASI monotherapy and combination treatment groups (Fig. 1d) .
Cumulative hazard analysis of endpoints of subcategories revealed similar results of the composite endpoint. Cerebral events in the RASI monotherapy group were significantly lower than in the combination treatment group (Table 2) . Table 3 shows follow-up blood pressure levels in each group. There were slight but significant differences in the systolic blood pressure levels between the combination treatment group and the untreated control or RASI monotherapy group over the 3-year follow-up periods.
Discussion
In this study, baseline covariates, including coronary risk factors such as hypertension, hyperlipidemia, impaired glucose tolerance and tobacco use, were adjusted between the control and treatment groups by the propensity score matching method [10] . As a result, additional effects beyond blood pressure lowering of an RASI and a CCB alone, or in combination were successfully evaluated. The findings of this study suggest that the usefulness of a combination of an RASI and a CCB beyond blood pressure lowing may not exist. This implies that the beneficial effects of the combination treatment with an RASI and a CCB compared with each monotherapy are largely due to the blood pressure lowering effects. In previous studies indicating the usefulness of combination therapy, blood pressure levels were significantly lower in the combination treatment groups [1] [2] [3] [4] . Thus, there may be no additional beneficial effects of a combination of an RASI and a CCB. This may be explained, at least in part, by the difference between the clinical situation and experimental study where a more than tenfold dose of a CCB was used to unravel the vascular protective effect of the drug [7] . Values are the mean ± SD or percentage of each characteristic Hypertension was defined as systolic blood pressure C140 mmHg or diastolic blood pressure C90 mmHg; hyperlipidemia was defined as total cholesterol C220 mg/dl or low density lipoprotein cholesterol C140 mg/dl or triglyceride C150 mg/dl CCB calcium channel blocker, RASI renin-angiotensin system inhibitor Although the RASI monotherapy was effective in terms of the prevention of cardiovascular events, the reason why the significantly favorable effect of an RASI disappeared with the addition of a CCB is unclear. The slight but significantly higher blood pressure in the combination treatment group as compared with the untreated control and RASI monotherapy groups may have counterbalanced the effectiveness of the combination treatment. Thus, there is a possibility that ''reversal of cause and effect'' may have been brought about in the present study.
In the blood pressure lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) [11] , 5,137 hypertensive patients with diabetes mellitus were randomized to amlodipine with addition of perindopril or atenolol with addition of thiazide, and were followed up for 5 years. The amlodipine-based treatment reduced the incidence of total cardiovascular events and procedures by 14% compared with the atenolol-based treatment. The mean systolic and diastolic pressures were 3.0 and 1.9 mmHg lower among those on the amlodipine-based treatment. Blood levels of glucose, creatinine and triglyceride throughout the study were significantly higher among patients on the atenolol-based treatment. The above-mentioned differences between the two treatment arms may explain the superiority of the combination of a CCB with an RASI to that of a beta-blocker with a diuretic.
In avoiding cardiovascular events by using combination therapy in patients living with systolic hypertension (ACCOMPLISH trial [12] ), the benazepril-amlodipine combination treatment has been demonstrated to be superior to the benazepril-hydrochlorothiazide combination in reducing cardiovascular events in high-risk patients with hypertension (relative risk reduction, 19.6%; p \ 0.001). Mean blood pressure after dose adjustment was significantly lower in the benezepril-amlodipine group compared with the benazepril-hydrochlorothiazide group. The mean difference in blood pressure between the two groups was 0.9 mmHg in the systolic and 1.1 mmHg in the diastolic readings. A small but significant difference in blood pressure may explain the superiority of the benezepril-amlodipine group resutls. Alternatively, the combination of a CCB with an RASI may provide unique beneficial effects beyond the blood pressure lowering effects as compared to the combination of an RASI with a diuretic. There are several limitations to the present study. First, it is likely that there is a bias related to individuals in this cohort treated with an RASI and/or a CCB being more severely ill than others. However, despite this residual bias, the hazard ratios tended to be lower in each of the drugtreated groups compared to the untreated control group (Fig. 1a, b, c) . The above-mentioned bias inherent to the observational study may have obviated the difference between the RASI monotherapy and combination treatment groups, because complete matching regarding risk factors, exercise [13] , drug usage [14] and severity of diseases between the two groups is difficult due to the limitation of the propensity score matching (Fig. 1d) . Second, in this study cohort, the prevalence of patients with hypertension was approximately 50-70%; therefore, it may be limited to extrapolating these results to patients with hypertension. Finally, randomization of patients to each treatment arm was not conducted, because the JCAD study was an observational, non-randomized trial. Thus, to clarify the usefulness of combination treatment beyond the blood pressure lowering effects, a prospective, randomized trial consisting of an RASI or a CCB monotherapy and combination treatment groups is needed, although the exact matching of blood pressure levels between the monotherapy and the combination treatment groups may be difficult. In conclusion, our findings suggest that there may be no additional prognostic benefit beyond blood pressure lowering effects in combination of an RASI and a CCB in patients with CAD.
